We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Bone-Disease Markers Monitor Response and Adherence to Osteoporosis Treatments

By LabMedica International staff writers
Posted on 04 May 2009
A range of automated bone-marker tests for the diagnostic and prognostic assessment of patients with or at risk of osteoporosis can be performed on a single serum work area platform. More...
The assays also provide an early indication of response and adherence to treatment.

The Elecsys range of bone marker, hormone, and bone mineral assays allows response to treatment and patient compliance to be monitored at an earlier stage (as early as three to six months after initiation of treatment) and throughout the course of treatment. This encourages adherence to treatment and provides medical staff with valuable information about its effectiveness. The traditional method for measuring response to treatment, bone mass densitometry (BMD), can take up to two years to demonstrate improvement to bone density

The comprehensive range of osteoporosis tests available from Roche Diagnostics (Burgess Hill, UK) for use with cobas or Modular Analytics serum work areas include the Elecsys bone-marker assays (ß-CrossLaps, total PINP [procollagen I N-terminal propertied], N-Mid Osteocalcin and vitamin D3-OH); the Elecsys hormone assays: parathormone, oestradiol, testosterone, dehydroepiandrosterone (DHEA) and sex hormone-binding globulin (SHBG); and bone mineral assays (calcium and phosphate).

According to the U.S. National Osteoporosis Society, one in two women and one in five men over the age of 50 will suffer a bone fracture, the main cause of which is osteoporosis. Among the most commonly used treatments for osteoporosis are the bisphosphonates. Although this group of drugs can be highly effective, gastric side effects and a complex treatment regimen can result in poor adherence. Alternative treatments, such as anabolic therapies, are more expensive, and therefore less likely to be prescribed as a first choice.

Roche is a world-leading healthcare company in the fields of diagnostics and pharmaceutics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis, and treatment of diseases. Roche is a developer of in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology.

Related Links:

Roche Diagnostics



New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.